- Home
- INVA vs STOK Comparison
INVA vs STOK Comparison
Compare INVA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | STOK |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | INVA | STOK |
|---|---|---|
| Price | $21.28 | $33.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $32.80 | ★ $39.20 |
| AVG Volume (30 Days) | 616.1K | ★ 742.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | 92.73 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $217,217,000.00 | $184,420,000.00 |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $12.65 | $77.49 |
| P/E Ratio | $16.94 | ★ N/A |
| Revenue Growth | 62.63 | ★ 404.50 |
| 52 Week Low | $16.52 | $18.80 |
| 52 Week High | $25.15 | $40.22 |
Technical Indicators
Market Signals| Indicator | INVA | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 60.00 |
| Support Level | $20.44 | $32.70 |
| Resistance Level | $21.91 | $34.62 |
| Average True Range (ATR) | 0.40 | 1.44 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 52.80 | 86.52 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.